SB

Scenic Biotech - Company Research Report



Company Overview



Name, Mission of the Company


  • Name: Scenic Biotech

  • Mission: To unlock the groundbreaking science of genetic modifiers and develop disease-modifying therapies to offer hope for patients with devastating conditions, including neuro- and metabolic diseases.


Founding Information


  • Founded: 2017

  • Founded By: Spin-out of the Netherlands Cancer Institute and Oxford University


Key People


  • CEO & Executive Director: Oscar Izeboud, PhD

  • CMO: Jens Würthner, MD, PhD

  • VP Legal: Margot Hoppe

  • VP Development: Annette Galler, PhD

  • Head People & Culture: Carola Jongerius


Board of Directors


  • Chairman: Philippe Dro

  • CEO & Executive Director: Oscar Izeboud, PhD

  • Independent Non-Executive Director: Ben Machielse, PhD

  • Non-Executive Director: Edward van Wezel, Simone Botti, PhD, Stéphane Verdood, Michael Wacker, Stephan Christgau, PhD

  • Founder & Board Observer: Prof. Thijn Brummelkamp

  • Board Observer: Nick Dixon-Clegg


Headquarters


  • Amsterdam Office: Science Park 301, 1098 XH Amsterdam, The Netherlands

  • New York Office: 136 Madison Avenue, 6th Floor, Manhattan, New York, NY 10016, USA


Number of Employees


No information is available

Revenue


No information is available

Company Recognition


  • Known for: Discovery of genetic modifiers to develop transformative therapeutics, especially focused on genetic disorders and severe diseases.


Products



Cell-Seq Platform


  • Description: Uses haploid human cells to discover genetic modifiers. These cells carry a single copy of every gene. Targets can be isolated via fluorescent labeling and FACS sorting followed by DNA sequencing.

  • Key Features:

  • Comprehensive overview of genetic modifiers.

  • Generation of high-resolution “disease maps”.

  • Unlocking disease-specific genetic modifiers and novel biological pathways.


Pipeline


Neuro and Metabolic Diseases


1. Niemann Pick Type C (NPC):
  • Target: Small-molecule inhibitors for NPC1 gene mutations.

  • Status: Preclinical studies ongoing.


2. Galactosemia:
  • Target: Small-molecule inhibitor against GALK.

  • Status: Preclinical studies initiated.


3. Other Programs:
  • X-ALD, Barth Syndrome, HSAN1, MacTel2.


Immunology


1. SC-2882 for Immuno-oncology:
  • Target: QPCTL, inhibiting CD47-SIRPα checkpoint.

  • Status: Completing IND-enabling studies.

  • Mechanism: Modifying chemokines to increase anti-tumor macrophage presence.


Recent Developments



New Partnerships


  • Research Collaboration with Bristol Myers Squibb: Investigating new potential partners to advance pipeline.

  • Cooperative Research with NIH: For Niemann-Pick Type C disease.


Recent Product and Feature Launches


  • QPCTL Inhibitor (SC-2882): Presented positive preclinical data showcasing potential as a treatment for diffuse large B-cell lymphoma (DLBCL).

  • Partnership with Barth Syndrome Foundation: Exploring genetic modifiers to find treatments for Barth Syndrome.


Management and Board Expansion


  • Ben Machielse Appointed to Board of Directors: Industry veteran with extensive drug development experience.

  • Jens Würthner Appointed as CMO: Bringing substantial clinical development expertise.


Contact Information


  • Email: info@scenicbiotech.com

  • Phone: +31 20 7059 990 (Amsterdam), +1 646 722 3322 (New York)


Further details and inquiries can be directed to the company's main contact points as listed above.